Sanoculis Overview
Sanoculis offers a new alternative surgical procedure for treating glaucoma. Its Minimally Invasive Micro Sclerostomy (MIMS) solution consists of a single-patient-use sterile tool and a multi-use external machine. In the course of the surgery, a sclero-corneal drainage channel is created to reduce intraocular pressure. MIMS is a microfluidic full-thickness procedure developed as an advanced laser sclerostomy. The technique uses a cutting and drilling device to reduce trauma to the surrounding tissue, minimizing scar tissue formation and allowing for a long-lasting filtering bleb. The MIMS channel ensures a controlled fluid flow with minor complications. In March 2017, Sanoculis was granted CE marking for its MIMS device and procedure.
Cumulative Funding Raised Over Time ($)
$1.0MAug 2016
$15.0MJul 2022
$18.5MSep 2019
Latest News
growth-positive
/PRNewswire/ -- Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, today announced that it has received CE Mark approval under...
Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, has received CE Mark approval under the Medical Device Regulation (MDR) in the EU for its MINT® product. MINT® is a stent-free technology platform designed for glaucoma angle surgery, offering a less invasive and more effective treatment option. The approval marks a significant milestone for Sanoculis, allowing them to proceed with a selective commercial pre-launch rollout later this year. The MINT® technology has shown promising results in clinical studies, indicating its safety and effectiveness in lowering intraocular pressure and reducing the need for glaucoma medications. This development is expected to enhance the standard of care for glaucoma patients.
Product Stage
growth-positive
/PRNewswire/ -- Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, today announced that it has received CE Mark approval under...
Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, has received CE Mark approval in the EU for its MINT® (Minimally Invasive Nasal Trabeculostomy) product. This innovative, stent-free technology platform is designed for the treatment of glaucoma and aims to improve patient outcomes by offering a less invasive, more effective treatment option. Clinical data indicates that MINT® is safe and effective in lowering intraocular pressure and reducing the need for glaucoma medications. Sanoculis plans a selective commercial pre-launch rollout of the MINT® technology later this year. The approval marks a significant step forward for the company, potentially elevating the standard of care in glaucoma treatment.
Product Stage
Growth-Positive
Eckuity Joins Bausch + Lomb in an Equity Investment in Sanoculis
Eckuity, a venture capital investor based in New York and London, has invested in Sanoculis, an Israeli ophthalmic medical device company, as part of a Series C funding round. Bausch + Lomb also invested and entered into an exclusive European distribution agreement with Sanoculis for its Minimally Invasive Micro Sclerostomy (MIMS®), a surgical procedure for glaucoma treatment. The companies have also entered into an option agreement, giving Bausch + Lomb the option to purchase all of Sanoculis assets.
InvestmentPartnersAcquisition
growth-positive
Bausch + Lomb and Sanoculis Announce Strategic Agreements Designed to Address Unmet Needs in Glaucoma
Bausch + Lomb Corporation has made an equity investment in Sanoculis, an Israeli ophthalmic medical device start-up, as part of a Series C funding round. The companies have also entered into an exclusive European distribution agreement for Sanoculis Minimally Invasive Micro Sclerostomy (MIMS), a surgical procedure for the treatment of glaucoma. The partnership aims to address unmet needs in glaucoma treatment, with MIMS offering a stentless, simple, and fast treatment that lowers intraocular pressure without invasive surgery. The companies have also entered into an option agreement, giving Bausch + Lomb the option to purchase all of Sanoculis assets.
InvestmentPartners
Neutral
News - Eyewire+
Eyewire+ is a platform that provides updates on the latest developments in the ophthalmic field. The information is sourced from press releases, medical journals, vision publications, videos, and other news sources.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $18.5M |
| Last funding | $14M |
| Stage | C |
| Rounds | 3 |
| Investors | 6 |
Team Members
4
Employees: 1-10
Web & Social Links
| Website | sanoculis.com |
Locations
Landau Street 10, Kiryat Ono, Israel
Photos & Videos
3 item(s)
Sanoculis Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
SensingLaserTags (11)
minimally-invasivesurgeryglaucomahospitalssurgeonsophthalmologymedical-deviceshealthcare-providerseye-diseasesclinicstreatmentsGeographic Markets
IndiaChinaEuropeSanoculis Financials
$18.5M
Total funding
Undisclosed
Capital raised
$14M
Last funding
C
Funding stage
3
Total rounds
6
Investors
Cumulative Funding Raised Over Time ($)
$1.0MAug 2016
$15.0MJul 2022
$18.5MSep 2019
Private Equity Funding
C Round
Jul 2022
$14M
Bausch + Lomb, Eckuity, Infinity Group
B Round
Sep 2019
$3.5M
HCS Capital , BIOLIGHT Life Sciences
A Round
Aug 2016
$1M
Zohar Zisapel (Late)
Sanoculis Lifecycle
Cumulative Funding Raised Over Time
$1.0MAug 2016
$15.0MJul 2022
$18.5MSep 2019
All Events
C Round
Jul 2022
$14M
Bausch + Lomb, Eckuity, Infinity Group
B Round
Sep 2019
$3.5M
HCS Capital , BIOLIGHT Life Sciences
A Round
Aug 2016
$1M
Zohar Zisapel (Late)
Sanoculis News
7 articles
growth-positive
/PRNewswire/ -- Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, today announced that it has received CE Mark approval under...
Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, has received CE Mark approval under the Medical Device Regulation (MDR) in the EU for its MINT® product. MINT® is a stent-free technology platform designed for glaucoma angle surgery, offering a less invasive and more effective treatment option. The approval marks a significant milestone for Sanoculis, allowing them to proceed with a selective commercial pre-launch rollout later this year. The MINT® technology has shown promising results in clinical studies, indicating its safety and effectiveness in lowering intraocular pressure and reducing the need for glaucoma medications. This development is expected to enhance the standard of care for glaucoma patients.
Product Stage
growth-positive
/PRNewswire/ -- Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, today announced that it has received CE Mark approval under...
Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, has received CE Mark approval in the EU for its MINT® (Minimally Invasive Nasal Trabeculostomy) product. This innovative, stent-free technology platform is designed for the treatment of glaucoma and aims to improve patient outcomes by offering a less invasive, more effective treatment option. Clinical data indicates that MINT® is safe and effective in lowering intraocular pressure and reducing the need for glaucoma medications. Sanoculis plans a selective commercial pre-launch rollout of the MINT® technology later this year. The approval marks a significant step forward for the company, potentially elevating the standard of care in glaucoma treatment.
Product Stage
Growth-Positive
Eckuity Joins Bausch + Lomb in an Equity Investment in Sanoculis
Eckuity, a venture capital investor based in New York and London, has invested in Sanoculis, an Israeli ophthalmic medical device company, as part of a Series C funding round. Bausch + Lomb also invested and entered into an exclusive European distribution agreement with Sanoculis for its Minimally Invasive Micro Sclerostomy (MIMS®), a surgical procedure for glaucoma treatment. The companies have also entered into an option agreement, giving Bausch + Lomb the option to purchase all of Sanoculis assets.
InvestmentPartnersAcquisition
growth-positive
Bausch + Lomb and Sanoculis Announce Strategic Agreements Designed to Address Unmet Needs in Glaucoma
Bausch + Lomb Corporation has made an equity investment in Sanoculis, an Israeli ophthalmic medical device start-up, as part of a Series C funding round. The companies have also entered into an exclusive European distribution agreement for Sanoculis Minimally Invasive Micro Sclerostomy (MIMS), a surgical procedure for the treatment of glaucoma. The partnership aims to address unmet needs in glaucoma treatment, with MIMS offering a stentless, simple, and fast treatment that lowers intraocular pressure without invasive surgery. The companies have also entered into an option agreement, giving Bausch + Lomb the option to purchase all of Sanoculis assets.
InvestmentPartners
Neutral
News - Eyewire+
Eyewire+ is a platform that provides updates on the latest developments in the ophthalmic field. The information is sourced from press releases, medical journals, vision publications, videos, and other news sources.
growth-positive
Alfred Mann's legacy stimulates Israeli innovation
The Mann Foundation for Biomedical Engineering and the Alfred Mann Institute at the Technion, both part of the legacy of late billionaire philanthropist and medical equipment entrepreneur Alfred Mann, are continuing to support medical equipment startups following Manns death. The Mann Foundation manages two funds that encourage applied research into startups at two universities, including the Technion Israel Institute of Technology. The foundation currently manages $85m and expects to increase this to $400m in the next two to three years.
InvestmentExpand
growth-positive
Minimally invasive micro sclerostomy may be alternative to trabeculectomy
Sanoculis, a medical technology company, has developed a new surgical technique called Minimally Invasive Micro Sclerostomy (MIMS) for treating patients with glaucoma. The technique combines the mechanism of conventional trabeculectomy and simple needling, and is designed to control intraocular pressure (IOP) with fewer complications. Preliminary trials of the MIMS procedure have shown promising results in primary open-angle glaucoma patients, with a 95.5% success rate in creating a drainage channel. However, long-term IOP control and morphological variations induced by conjunctival or sclera fibrotic changes need to be evaluated in future studies.
Customers
Sanoculis Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 9 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Sanoculis Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 99/100 |
| Missing | markets |
| BI Verification | Natalia Golczar |
| Registrar ID | 514733724 |
| Crunchbase | sanoculis |
| Phone | +97235503432 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-02-15T00:00:00.000Z |
| Created | 2015-01-06T00:00:00.000Z |
| Claimed | Yes |